source
- AstraZeneca says phase 3 ADC shows strong overall survival despite missing progression-free survival endpointAstraZeneca executives emphasized that the detailed data from their phase 3 study of the next‑generation antibody‑drug conjugate are robust enough to be presented to regulators, even though the tri…
- AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in MadridAt the European Society for Medical Oncology (ESMO) congress in Madrid, nearly 40,000 delegates gathered for the five-day meeting. AstraZeneca said it is evaluating the use of its immunotherapy Ke…